Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
ARQT on Nasdaq
Shares outstanding
122,541,881
Price per share
$25.87
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
128,891,439
Total reported value
$3,742,417,598
% of total 13F portfolios
0.01%
Share change
+2,568,387
Value change
+$102,234,176
Number of holders
277
Price from insider filings
$25.87
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Frazier Life Sciences VIII, L.P. 7.5% $130,399,321 8,943,712 Patrick J. Heron 18 Aug 2025
Rubric Capital Management LP 6.8% $239,875,733 8,271,577 Rubric Capital Management LP 31 Dec 2025
PRUDENTIAL FINANCIAL INC 5.7% -44% $205,317,854 -$141,350,176 7,079,926 -41% PRUDENTIAL FINANCIAL INC 31 Dec 2025
JENNISON ASSOCIATES LLC 5.5% -47% $196,252,494 -$159,607,122 6,758,006 -45% Jennison Associates LLC 31 Dec 2025
Polar Capital Holdings Plc 4.2% -24% $75,147,145 -$25,517,045 5,006,472 -25% Polar Capital Holdings Plc 30 Jun 2025

As of 31 Dec 2025, 277 institutional investors reported holding 128,891,439 shares of Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT). This represents 105% of the company’s total 122,541,881 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SUVRETTA CAPITAL MANAGEMENT, LLC 9.8% 11,964,000 +14% 8.7% $347,434,560
Frazier Life Sciences Management, L.P. 8.1% 9,874,511 0% 7.7% $286,755,799
BlackRock, Inc. 7.4% 9,099,579 +6.1% 0% $264,251,774
Rubric Capital Management LP 6.8% 8,271,577 -23% 2.9% $240,206,596
VANGUARD GROUP INC 5.9% 7,253,936 +1.5% 0% $210,654,301
JENNISON ASSOCIATES LLC 5.5% 6,758,006 -45% 0.12% $196,252,495
Polar Capital Holdings Plc 4.5% 5,556,169 +4.9% 0.74% $161,351,148
STATE STREET CORP 4.5% 5,488,301 +18% 0.01% $159,380,261
GILDER GAGNON HOWE & CO LLC 3.6% 4,453,856 +0.56% 1.4% $129,339,978
MORGAN STANLEY 3.5% 4,340,238 +1.5% 0.01% $126,040,515
UBS Group AG 2.6% 3,243,432 +10% 0.02% $94,189,265
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,753,307 +5.6% 0% $79,967,495
D. E. Shaw & Co., Inc. 2.2% 2,683,087 +27% 0.06% $77,916,846
Driehaus Capital Management LLC 2.1% 2,562,445 +134% 0.51% $74,413,403
Ensign Peak Advisors, Inc 1.6% 1,902,390 -4.5% 0.1% $55,245,406
FRANKLIN RESOURCES INC 1.6% 1,900,084 -18% 0.01% $55,178,440
JANUS HENDERSON GROUP PLC 1.5% 1,830,061 -24% 0.02% $53,154,122
BANK OF AMERICA CORP /DE/ 1.4% 1,673,454 +88% 0% $48,597,105
GOLDMAN SACHS GROUP INC 1.3% 1,576,413 -13% 0.01% $45,779,034
AMERICAN CENTURY COMPANIES INC 1.2% 1,467,176 -12% 0.02% $42,606,849
Nuveen, LLC 1.1% 1,382,160 +0.86% 0.01% $40,137,927
Pivotal bioVenture Partners Investment Advisor LLC 1.1% 1,366,624 -36% 15% $39,686,761
PRICE T ROWE ASSOCIATES INC /MD/ 0.95% 1,166,348 +1228% 0% $33,872,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 1,014,826 +1.5% 0% $29,470,547
GW&K Investment Management, LLC 0.82% 1,008,580 -14% 0.25% $29,289,000

Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 128,891,439 $3,742,417,598 +$102,234,176 $29.04 277
2025 Q3 125,804,940 $2,370,184,094 -$12,772,142 $18.85 235
2025 Q2 127,080,415 $1,781,069,063 +$21,637,125 $14.02 228
2025 Q1 125,020,441 $1,954,466,256 -$63,284,061 $15.64 239
2024 Q4 128,710,441 $1,792,934,402 +$13,789,213 $13.93 206
2024 Q3 128,641,664 $1,198,282,493 +$15,921,001 $9.30 187
2024 Q2 126,503,507 $1,176,619,915 +$9,242,287 $9.30 184
2024 Q1 124,986,945 $1,238,517,575 +$285,414,998 $9.91 166
2023 Q4 101,272,913 $327,119,655 +$79,248,549 $3.23 130
2023 Q3 67,159,664 $356,705,615 -$26,597,323 $5.31 131
2023 Q2 71,766,867 $683,988,878 -$5,745,956 $9.53 135
2023 Q1 71,600,840 $787,595,702 +$44,255,428 $11.00 141
2022 Q4 65,632,382 $971,340,873 +$87,400,990 $14.80 138
2022 Q3 59,389,299 $1,134,920,691 +$194,978,652 $19.11 138
2022 Q2 49,075,739 $1,045,833,934 +$17,642,019 $21.31 112
2022 Q1 48,307,139 $929,780,885 -$136,426,148 $19.26 106
2021 Q4 46,348,278 $961,255,152 -$1,852,441 $20.74 89
2021 Q3 45,697,453 $1,091,410,573 +$4,816,184 $23.89 103
2021 Q2 45,474,760 $1,240,848,739 -$38,040,013 $27.29 100
2021 Q1 46,841,365 $1,354,985,371 +$170,660,745 $28.93 93
2020 Q4 40,973,719 $1,152,598,120 +$138,537,380 $28.13 78
2020 Q3 34,766,158 $1,018,651,387 +$28,894,471 $29.30 62
2020 Q2 33,776,828 $1,021,408,758 +$33,104,690 $30.24 55
2020 Q1 32,683,658 $973,975,747 +$973,295,747 $29.80 49